Inflammatory Diseases
Naïve, protein-naïve and non-naïve study subjects.
Acute, short-infusion or repeated dosing designs.
General, tissue and cell-specific inflammatory evaluations.
Full clinical chemistry, clinical pathology and clinical toxicology support.
Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.
Organ-specific or complete histology and pathology evaluation.
Extensive inflammation models in cynomolgus and marmosets with functional and clinical assessments:
- Dermal inflammation: DI
- Irritable bowel diseases: IBD
- Multiple sclerosis: MS
- Respiratory/asthma/COPD: RAC
- Sepsis/ endotoxemia: ET
- Wound healing: WH
Comprehensive inflammation biomarkers assays:
- Standard and expanded multiplexed cytokine assays
- Immune markers (comprehensive CD markers panels by flow cytometry)
- Acute phase proteins assays (CRP and SAA)
- Cellular lipid markers assays
